The pharmaceutical company co-led a series C round for AAV gene therapy developer Freeline that took its total funding to $275m.

UK-based gene therapy developer Freeline closed a $120m series C round today that was co-led by pharmaceutical firm Novo, investment adviser Eventide Asset Management and investment management firm Wellington Management. The round included commercialisation firm Syncona, which supplied $40m in a December 2019 first tranche, as well as Cowen Healthcare Investments, Acorn Bioventures and Ample…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.